anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The utility model discloses an anoectochilus formosanus drying device which is a dying box. The drying box comprises a box body and a rotating mechanism. The rotating mechanism comprises a rotating shaft driven by a motor and longitudinally arranged in the box body, and a plurality of drying plates installed on the rotating shaft. The rotating shaft is provided with two longitudinal sliding grooves which are symmetrically distributed. Each drying plate is arranged on the outer side of the rotating shaft in a sleeved mode, and the drying plates are matched with the longitudinal sliding grooves through buckles on the inner sides of the drying plates to form a lifting mechanism. According to the anoectochilus formosanus drying device, on the basis of the prior art, the lifting mechanism and a self-locking device matched with the lifting mechanism are added, so that lifting of each drying plate is achieved, working steps are simplified, strength is reduced, convenience is brought to practical use, working time is shortened, and working efficiency is improved. In addition, a sensor is added, and therefore real-time observation and control over the temperature and the humidity in the box body are achieved.
Patients deemed to be at intermediate to high risk for postoperative cardiovascular events by clinical criteria will be the subject of this study. Cardiac risk will be determined according to the Revised Cardiac Risk Index (RCRI). RH-PAT testing and BNP evaluation will take place within 30 days before surgery and may occur on separate days. The blood may be drawn on the day of the RH-PAT testing or at a time of routine blood drawing within the 30 day period. After surgery the patient will be monitored and examined in the PACU for evidence of cardiac events.
This study is a prospective, randomized, single center, controlled explorative study in the parallel-group design to evaluate the difference in clinical outcomes for patients with metastatic spine disease treated with a whole versus partial vertebral body contouring approach. Thereby two different techniques were evaluated: whole vertebral body (WB) group with 10 x 3Gy or partial vertebral body (PB) group with 10x (3-5)Gy. Prior to their enrolment into the study, the patients will undergo a staging of the vertebral column in connection with their radiation-planning computed tomography (CT) and MRI to measure the myelon dimension. After the baseline results have been recorded, the patients will be randomized into one of the two groups: PB group RT 10x (3-5) Gy (n = 30) or WB group RT 10 x 3 Gy (n = 30). The target parameters will be measured and recorded at baseline, at 1 to 2 weeks; and at months 2 to 3, 4 to 6 and 7 to 12 after treatment.

The primary endpoint was the time to pain relief. Secondary endpoints were quality of life (QoL), fatigue, pain, overall survival, bone survival, local control, pathological fracture, pain-free internal and neurological deficit. The baseline examination shall be carried out on the first day of radiotherapy prior to the start of therapy and is scheduled to comprise the comprehensive recording of the sociodemographic data, the recording of the current pain situation, the quality of life, and the current degree of fatigue. The follow-up examinations shall take place at each follow up visit , measuring those parameters recorded at the baseline examination. The further follow-up examinations shall correspond to those carried out as standard after-care investigations.

The secondary endpoints such as fatigue and quality of life shall be recorded using validated questionnaires (EORTC QLQ FA13 and EORTC QLQ BM22. All patients will also be asked to record their pain history using a pain diary (documentation of medication daily during treatment, once weekly after the end of treatment, VAS pain scale). Furthermore, the local control was assessed by means of CT images taken prior to, three and six months after RT. The pain response was documented on the VAS (range 0-10). Complete response (CR) was defined as VAS = 0 after three and six months, partial response (PR) as an improvement by at least two score points after three and six months. Overall survival (OS) was defined as time from initial diagnosis until death, bone survival as time from initial diagnosis of spinal bone metastasis until death.

In each case, the treatment plan was designed based on tumor geometry, proximity to the spinal cord, and location. The planning tumor volume (PTV) was defined as equal to gross tumor volume (GTV). The spinal cord, cauda equina, nerve roots, and bowel were contoured as organs at risk (OARs) and critical structures. An inverse treatment planning method along with a linear optimization algorithm were employed. The target volume was designated to include either the GTV and the entire vertebral body (WB group) or only the GTV (PB group) at each spinal level.
This is a registry database. Consented subjects will have their medical data collected via a patient questionnaire in either paper or web based application form. Data will be collected prospectively and retrospectively and will be entered into the database generated by Memorial Bone and Joint Research Foundation. Collection of data will start during the initial clinic visit as part of standard of care. Subjects will be asked to fill out a 4-page "pre-operative hip questionnaire" or "pre-operative knee questionnaire", which includes questions for self-assessment from the Hip Disability and Osteoarthritis Outcome Score (HOOS), Knee disability and Osteoarthritis Outcome Score (KOOS), EQ-5D and University of California, Los Angeles Activity (UCLA) questionnaires. Demographic, intra-operative and additional data will also be collected to correctly identify the subject's specific disease process and treatment plan. Subjects will be asked to fill out a post-operative hip and knee questionnaire that is similar to the pre-operative questionnaire to evaluate the improvement in their clinical outcomes. The subjects will be requested to complete the post-operative questionnaires at 6 months and annually thereafter.
BACKGROUND: Peritoneal fibrosis is the prevailing complication induced by prolonged exposure to high glucose in patients undergoing peritoneal dialysis.
METHODS: To elucidate the molecular mechanisms underlying this process, we conducted an integrated analysis of the transcriptome and chromatin accessibility profiles of human peritoneal mesothelial cells (HMrSV5) during high-glucose treatment.
RESULTS: Our study identified 2775 differentially expressed genes (DEGs) related to high glucose-triggered pathological changes, including 1164 upregulated and 1611 downregulated genes. Genome-wide DEGs and network analysis revealed enrichment in the epithelial-mesenchymal transition (EMT), inflammatory response, hypoxia, and TGF-beta pathways. The enriched genes included VEGFA, HIF-1α, TGF-β1, EGF, TWIST2, and SNAI2. Using ATAC-seq, we identified 942 hyper (higher ATAC-seq signal in high glucose-treated HMrSV5 cells than in control cells) and 714 hypo (lower ATAC-seq signal in high glucose-treated HMrSV5 cells versus control cells) peaks with differential accessibility in high glucose-treated HMrSV5 cells versus controls. These differentially accessible regions were positively correlated (R = 0.934) with the nearest DEGs. These genes were associated with 566 up- and 398 downregulated genes, including SNAI2, TGF-β1, HIF-1α, FGF2, VEGFA, and VEGFC, which are involved in critical pathways identified by transcriptome analysis. Integrated ATAC-seq and RNA-seq analysis also revealed key transcription factors (TFs), such as HIF-1α, ARNTL, ELF1, SMAD3 and XBP1. Importantly, we demonstrated that HIF-1α is involved in the regulation of several key genes associated with EMT and the TGF-beta pathway. Notably, we predicted and experimentally validated that HIF-1α can exacerbate the expression of TGF-β1 in a high glucose-dependent manner, revealing a novel role of HIF-1α in high glucose-induced pathological changes in human peritoneal mesothelial cells (HPMCs).
CONCLUSIONS: In summary, our study provides a comprehensive view of the role of transcriptome deregulation and chromosome accessibility alterations in high glucose-induced pathological fibrotic changes in HPMCs. This analysis identified hub genes, signaling pathways, and key transcription factors involved in peritoneal fibrosis and highlighted the novel glucose-dependent regulation of TGF-β1 by HIF-1α. This integrated approach has offered a deeper understanding of the pathogenesis of peritoneal fibrosis and has indicated potential therapeutic targets for intervention.
Background: Obesity is a predisposing risk factor for type 2 diabetes mellitus (T2DM). Actually, not only obese/overweight but also nonobese/lean individuals may be prone to T2DM. This study is aimed at identifying the contribution of adipose tissue to the development of nonobese diabetes (NOD) and obese diabetes (OD). Methods: Serum samples from the nonobese nondiabetes (NOND, n = 47, age = 46.8 ± 8.4, BMI ≤ 23.9 kg/m2) controls, NOD (n = 48, age = 50.7 ± 6.5, BMI ≤ 23.9 kg/m2) and OD (n = 65, age = 49.8 ± 10.2, BMI ≥ 28 kg/m2) patients were utilized to measure the expression of metabolic indicators, adipocytokines, inflammatory factors. Different adipose depots from offspring with corresponding blood glucose and obesity levels of a spontaneously diabetic gerbil line with various degrees of diabetic penetrance and body weights were examined for adipocytokines and inflammation factors detected by ELISA and western blot. Adipose tissue volume and fat cell size of the gerbils were evaluated by magnetic resonance imaging and immunohistochemistry, respectively. Results: The study yielded four key findings. Firstly, in comparison to the NOD group, the OD group exhibited more severe insulin resistance (IR) and metabolic dysfunction in both patients and gerbils, attributed to higher visceral adipose tissue mass and larger fat cell sizes. Secondly, in gerbils, gonadal fat deposition was linked to obesity development, whereas kidney fat deposition correlated with obesity and diabetes occurrence. Thirdly, in both patients and gerbils, the interplay between adiponectin and leptin levels in serum may significantly influence the development of obesity and diabetes. Lastly, heightened expression of MCP3 in gerbils' kidney adipose tissue may serve as a pivotal factor in initiating obesity-associated diabetes. Conclusions: Our study, which may be considered a pilot investigation, suggests that the interaction of adipocytokines and inflammation factors in different adipose depots could play diverse roles in the development of diabetes or obesity.
1,182,555. Anti-mastitis vaccine. SAPHAR LABORATORIES Ltd. 22 Aug., 1968 [16 Oct., 1967], No. 40126/68. Heading A5B. Anti-mastitis vaccine in unit dosage form includes detoxified alpha toxins, leucocidin and surface antigens, all made from mastitis Staphylococcus aureus. Alpha toxins and leucocidins are prepared by clarifying the culture filtrate in a centrifuge, adding formalin or beta-propiolactone and absorbing the solution on lead acetate, eluting with sodium phosphate, precipitating the eluate with ammonium sulphate, drying or re-dissolving and freezedrying the precipitate. The surface antigens are prepared by separating the bacteria in a centrifuge, extracting with phenol-water and precipitating them with ammonium sulphate. The vaccine is administered intranasally, intramammarily or intravaginally in the form of drops, tablets, solutions or powders.
Not for direct patient injection. Potassium Chloride for Injection Concentrate USP, Pharmacy Bulk Package is for preparation of intravenous admixtures only and must be diluted before administration. Care must be taken to ensure there is complete mixing of the potassium chloride with the large volume fluid, particularly if soft or bag type containers are used.

Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

Dosage and rate of administration are to be directed by the physician and are dependent upon the specific conditions of each patient (e.g., age, weight, clinical condition of the patient and laboratory determinations). Frequent laboratory determinations and clinical evaluation are essential to monitor changes in electrolyte concentrations, and fluid and electrolyte balance during prolonged parenteral therapy.

If the serum potassium level is greater than 2.5 mEq/liter, potassium can be given at a rate not to exceed 10 mEq/hour and in a concentration of up to 40 mEq/liter. The 24 hour total dose should not exceed 200 mEq.

If urgent treatment is indicated (serum potassium level less than 2.0 mEq/liter and electrocardiographic changes and/or muscle paralysis), potassium chloride may be infused very cautiously at a rate of up to 40 mEq/hour. In such cases, continuous cardiac monitoring is essential. As much as 400 mEq may be administered in a 24 hour period. In critical conditions, potassium chloride may be administered in saline (unless contraindicated) rather than in dextrose containing fluids, as dextrose may lower serum potassium levels.
INTRODUCTION: FAK, a nonreceptor cytoplasmic tyrosine kinase, plays a crucial role in tumor metastasis, drug resistance, tumor stem cell maintenance, and regulation of the tumor microenvironment. FAK has emerged as a promising target for tumor therapy based on both preclinical and clinical data.
AREAS COVERED: This paper aims to summarize the molecular mechanisms underlying FAK's involvement in tumorigenesis and progression. Encouraging results have emerged from ongoing clinical trials of FAK inhibitors. Additionally, we present an overview of clinical trials for FAK inhibitors, examining their potential as promising treatments. The pertinent studies gathered from databases including PubMed, ClinicalTrials.gov.
EXPERT OPINION: Since the first finding in 1990s, targeting FAK has became the focus of interests in many pharmaceutical companies. Through 30 years' discovery, the industry and academy gradually realized the features of FAK target which may not be a driver gene but a solid defense system for the cancer initiation and development. Currently, the ongoing clinical regimens involving FAK inhibition are all the combination strategies in which FAK inhibitors can further strengthen the cancer cell killing effects of other testing agents. The emerging positive signal in clinical trials foresee targeting FAK as class will be an effective mean to fight against cancers.
Two-period single p.o. dose fasted/fed crossover separated by 5-day washout period. Dose to be determined by review of data from Part 2.
Respiratory depression is the primary risk of oxycodone hydrochloride. Respiratory depression occurs more frequently in elderly or debilitated patients and in those suffering from conditions accompanied by hypoxia, hypercapnia, or upper airway obstruction, in whom even moderate therapeutic doses may significantly decrease pulmonary ventilation.

Use oxycodone hydrochloride with extreme caution in patients with chronic obstructive pulmonary disease or cor pulmonale and in patients having a substantially decreased respiratory reserve (e.g., severe kyphoscoliosis), hypoxia, hypercapnia, or preexisting respiratory depression. In such patients, even usual therapeutic doses of oxycodone hydrochloride may increase airway resistance and decrease respiratory drive to the point of apnea. Consider alternative non-opioid analgesics, and use oxycodone hydrochloride only under careful medical supervision at the lowest effective dose in such patients.

Oxycodone hydrochloride 100 mg per 5 mL (20 mg per mL) oral solution is for use in opioid-tolerant patients only. Administration of this formulation may cause fatal respiratory depression when administered to patients who are not tolerant to the respiratory depressant effects of opioids.
It is intended to provide a composition for regulating the activity of regulatory T cells and a regulation method. Namely, a composition containing an antigen recognized by CD4+CD25+ regulatory T cells or an expression vecto r encoding the antigen and a method of regulating an immune response of a mamm al by administering the composition to the mammal. Thus, means useful in preventing and treating autoimmune diseases and allergic diseases and inhibiting rejection reaction and graft-versus-host reaction in transplantation is provided. Furthermore, the immunosuppressive state is relieved by administering interferon .gamma. or administering a combination of interleukin 12 with interleukin 18. That is to say, regulatory T cells can b e artificially controlled by appropriately combining the action of such a cytokine with the sensitization with SEREX antigen, which is applicable to autoimmune diseases, reactions accompanying organ transplantation, allergic reactions, regulation of tumor immunity and so on.
Apparatus and method for retrieving similar findings (especially for medical condition diagnosis) from a hybrid image dataset, comprising: preparing a database of hotspots (local maxima) identified by binary strings encoding descriptors; aligning 10 functional (eg. PET, SPECT) and anatomical modality (eg. CT, MRI) image datasets to form the hybrid dataset; normalising 20 the functional image data; identifying and segmenting 30 local maxima regions of interest in the image data; defining bounding boxes 40 for the regions of interest (ROI) in the image dataset; calculating descriptors for the regions in the bounding boxes and encoding them into new binary strings; identifying binary strings in the database that resemble the new binary strings through comparison 50. Descriptors may relate to image intensity or localisation eg. histograms or vector displacements from anatomical landmarks. Thresholding may be used. Image regions corresponding to local maxima strings may be presented 60 on a display along with annotations or metadata. Image regions in the database may have bounding boxes with same dimensions as those for the new region of interest.
This study sought to determine whether a 2-week regimen of spinal manipulative therapy could improve postural control under 2 conditions. Condition one was a complex postural task which consisted of a shoulder width stance on a compliant surface with eyes closed to remove visual input. Condition 2 was as above with the addition of visio-spatial cognitive task (serial 7s subtraction). These tasks were performed on a force-place designed to capture center of pressure data. Data was captured prior to the onset of therapy and then again after 6 treatment sessions (2-week period). Data was also collected 1 week post treatment to note any lasting effects following therapy. This pilot study utilized a repeated measures designed with no control group.
Disclosed are hair care compositions and methods for preparing such compositions which provide the benefits of cleaning, conditioning, curl retention, styling and setting properties simultaneously to hair in the application of a single product. The hair care compositions contain fatty alkyl amine salts, long chain quaternary ammonium salts and mixtures thereof of anionic styling polymers in a non-anionic surfactant system, wherein the surfactant system contains nonionic surfactants, semi-polar nonionic surfactants, amphoteric surfactants and mixtures thereof. The styling, setting and conditioning agents are present in the form of fatty alkyl amine salts or fatty quaternary ammonium salts which form anionic styling polymer particulate networks upon dilution in water. These networks are dispersed in the aqueous non-anionic surfactant system and are stabilized and thickened by optional swellable polymer thickening agents. Hair care compositions of the present invention can be made in the form of structured liquids, pearlescent/opaque isotropic liquid and/or translucent/clear isotropic liquids. The hair care compositions of the present invention, which allow for re-styling of the hair by wetting the hair with water, contain no anionic surfactants, silicones, solvents or cationic polymeric conditioning agents. Furthermore, multiple application of these hair care compositions does not produce a noticeable build-up on the hair.
Background: Low Back Pain (LBP), one of the most critical disability causatives, has been associated with neuromuscular and biomechanical manifestations related to the deficiency of postural control and stability. Virtual reality (VR) core stabilization exercises (CSE) has proven previously to be effective in improving postural control among conditions with different proprioceptive damage mechanisms other than those affected with LBP. The Aim of this study is to explore the differing effects of this treatment regimen on postural stability in relation to lumbar and ankle proprioception among in a population of participants with LBP. Design and Methods: a randomized clinical trial encompassing 44 participants of both genders. Participants with Chronic Low Back Pain (CLBP) will be randomized to one of two treatment groups: an Experimental group receiving VR stabilization exercises and a Control group receiving CSE only without VR simulations inaddition to patient instructions and education of both groups. Parameters of postural stability, ankle and trunk proprioception, pain intensity, balance interference with activity and psychological aspects of pain interference with activity will be measured by a force plate, iPhone applications, visual analog scale (VAS), the Activities-specific Balance Confidence (ABC) scale, Pain Catastrophizing Scale (PCS) and the Pain Self-Efficacy Questionnaire (PSEQ-Ar) respectively. Outcome measures will be collected at baseline, immediately after 1st treatment and after the last treatment session. Treatment regimens will consist of 12 sessions in 3 weeks using virtual reality glasses. Statistical Analysis: A mixed-model repeated-measures analysis of variance will be used to analyze within- and between-group differences at the baseline, 6th session and twelfth sessions (repeated measures will be set as GROUP with two levels and TIME with three levels). Bonferroni post-hoc procedures will be used for multiple comparisons of the differences over time. Intention-to-treat analysis shall be utilized. Statistical significance was set at P \< 0.05.
Kijanimicin and its salts were prepd. by the cultivation of a strain of Actinomadura kijaniata.  Thus, the inoculum of A. kijaniata was prepd. in three stages by inoculation in vegetative media by the usual methods.  The final fermn. was carried out by inoculation of the inoculum in a 10L medium comprising yeast ext., glucose, sol. starch, NZ amine, CaCO3, and CoCl2 at pH 7.0 at 27-35≰C with aeration and agitation.  Kijanimicin was isolated y extn. with EtOAc and evapd. until dry.  After redissolving the product in Me2CO it was pptd. (30.1g), filtered, and dried and then further purified on silica gel to yield 5.5g Kijanimicin(I).  I displays activity against acne, tumors, malaria, bacteria, and inflammations.  The Na salt of I was also produced.
FIELD: medicine. SUBSTANCE: method is based on artificial lungs ventilation and use of medicinal therapy. Method eliminates the use of anticholine esterase preparations and patient is subjected for artificial lung ventilation up to recovery of spontaneous breathing followed by urgent discrete plasmaphoresis carrying out. Plasma substitution is 0.8 volume of circulating plasma of patient (not less) at simultaneous erythrocyte membranes washing off. Single blood volume taking off is 12-15% of circulating blood of patient followed by centrifugation at rate 2900-3100 rev/min for 5-8 min. Leukocyte removing enhances immunosuppressing effect of plasmaphoresis. Erythrocyte membranes were washed off twice that promotes the removing pathological substances from membranes (antigens, antibodies and immune complexes causing damage of nerve-muscle transmission), accelerates their removing with plasma and rapid arresting the respiratory attack. EFFECT: improved method of treatment.